Thomas Michael, Mousa Shaymaa S, Mousa Shaker A
Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
Clin Ophthalmol. 2013;7:495-501. doi: 10.2147/OPTH.S29974. Epub 2013 Mar 8.
Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now considered the standard of care. Anti-VEGF agents inhibit angiogenesis in the eye by suppressing abnormal blood vessel growth, leading to vision improvement. Ranibizumab and bevacizumab are two examples of anti-VEGF drugs that have been approved; both showed promise based on the visual acuity scale. Aflibercept, another new therapy known to trap VEGF and inhibit multiple growth factors, is promising not only because it can be taken bimonthly based on year 1 of the VIEW trials, but it can also be extended, as demonstrated in year 2 of the VIEW trials. Based on a cost-effect analysis, aflibercept is comparable to other leading therapies. This is a review of relevant clinical trials that have proven the non-inferiority and safety of aflibercept compared to the standard of care and its unique role in the current management of wet AMD.
湿性年龄相关性黄斑变性（AMD）是美国视力丧失的最常见原因。人们已经采用了许多治疗方法，如激光疗法和光动力疗法，但它们的疗效有限。新兴的抗血管内皮生长因子（VEGF）疗法现在被视为标准治疗方法。抗VEGF药物通过抑制异常血管生长来抑制眼部血管生成，从而改善视力。雷珠单抗和贝伐单抗是两种已获批的抗VEGF药物；二者在视力表方面均显示出前景。阿柏西普是另一种已知可捕获VEGF并抑制多种生长因子的新疗法，它很有前景，这不仅是因为根据VIEW试验的第1年情况它可以每两个月给药一次，而且正如VIEW试验第2年所表明的，它还可以延长给药时间。基于成本效益分析，阿柏西普与其他领先疗法相当。这是一篇关于相关临床试验的综述，这些试验证明了阿柏西普相对于标准治疗方法的非劣效性和安全性，以及它在当前湿性AMD治疗中的独特作用。
